A phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (LA BCC) – the SONIBEC trial
Publication date: 2026 Source: EJC Skin Cancer, Volume 4 Author(s): Carlo Resteghini, Monica Variolo, Sara Farinatti, Andrea Alberti, Valeria Tovazzi, Paola Queirolo, Maristella Saponara, Giuseppe Agenziano, Riccardo Marconcini, Ketty Peris, Paola Savoia, Maria Chiara Tronconi, Iris Zalaudek, Paolo Antonio Ascierto, Francesco Spagnolo, Luigi Lorini, Cristina Gurizzan, Filippo Chersi, Paolo Bossi
A phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (LA BCC) – the SONIBEC trial. // EJC Skin Cancer. – URL: https://www.sciencedirect.com/science/article/pii/S2772611826003745?dgcid=rss_sd_all
A phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (LA BCC) – the SONIBEC trial. EJC Skin Cancer. https://www.sciencedirect.com/science/article/pii/S2772611826003745?dgcid=rss_sd_all
“A phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (LA BCC) – the SONIBEC trial.” EJC Skin Cancer.
@article{article44203,
title = {A phase II, open-label study to improve compliance and time of treatment after obtaining complete response (CR) through a tailored schedule of sonidegib in locally advanced basal cell carcinomas (LA BCC) – the SONIBEC trial},
journal = {EJC Skin Cancer},
url = {https://www.sciencedirect.com/science/article/pii/S2772611826003745?dgcid=rss_sd_all}
}
Nature Reviews Cancer, Published online: 19 November 2026; doi:10.1038/s41568-026-01001-2 In this Journal Club, Chien-Han Kao and Ruey-Hwa Chen discuss a study showing that tumours use both de novo purine biosynthesis and purine salvage...
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01779-2 Targeting SMYD3 in cancer-associated fibroblasts relieves immune suppression and improves anti-PD-L1 response in HPV-negative HNSCC
npj Precision Oncology, Published online: 19 November 2026; doi:10.1038/s41698-026-01786-3 Postoperative timing effects on AI-based resection-cavity segmentation in glioma: multi-site evaluation and relevance assessment